Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : bluebird bio Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Biotech Jim who wrote (20)	12/4/2013 11:00:52 AM
From: Biotech Jim	1 Recommendation Recommended By rkrw Respond to of 163

Those of us that participated in the genomic revolution realize that it takes a while to appreciate that the revolution is happening, in part because there is so much to learn to successfully practice the technology. The revolution in the immunologic approaches to cancer started a while back, and it was not until the recent clinical successes that some or many understood that we were witnessing the revolution taking place. The current revolution is the cancer immunotherapy revolution, and its predecessor in the oncology field was and is the 'targeted therapy' revolution. Some revolutions in science are bigger than others. The genomic revolution allowed for the other two revolutions mentioned above. Here is the Fred Hutchinson Cancer Research Center ( the Hutch) press release on Juno Therapeutics. It now seems likely that most if not all of the Memorial Sloan Kettering CAR T work is rolled into this company. Michel Sadelain, MD, PhD is one of the founding scientists of Juno, and he was a listed co-author on the ASH abstract mentioned previously. fhcrc.org